Introduction {#s1}
============

Circadian rhythms are repetitive \~24 hr cycles that allow organisms to temporally align behavioral, biochemical and physiological processes with daily environmental changes ([@bib65]; [@bib39]; [@bib4]). These rhythms exist in virtually all mammalian cells and are generated by transcriptional/translational feedback loops referred to as the molecular-clock ([@bib40]; [@bib61]; [@bib59]). The positive limb of the core clock is comprised of the PAS domain containing basic-Helix-Loop-Helix factors (PAS-bHLH) core clock factors Brain and Muscle Arnt-Like 1 (*Bmal1*) and Circadian Locomotor Output Clocks Kaput (*CLOCK*). These factors heterodimerize and bind to the DNA at E-box elements where they generate circadian transcription oscillations through rhythmic recruitment of histone acetylases, co-factors, and components of the transcriptional complex ([@bib25]; [@bib8]; [@bib40]). In addition to keeping time, the core molecular clock factors regulate the expression of downstream clock-controlled genes (CCGs), many of which encode master transcriptional regulators and rate-limiting enzymes in key biochemical pathways ([@bib5]; [@bib6]).

Although the core molecular clock components are expressed in the majority of cell-types throughout the body, CCGs are expressed in a very tissue-specific fashion ([@bib58]; [@bib71]; [@bib35]). This temporal regulation of tissue-specific gene programs allows for the timing of organ and cell-type specific processes that help maintain physiological homeostasis within each tissue and across multiple organ systems throughout the day ([@bib6]; [@bib27]). The transcriptional mechanisms by which the core clock factors regulate tissue-specific genes are not fully understood. Recent studies have begun to identify lineage-specific transcriptional regulators that co-localize with molecular clock components at cis-regulatory elements located within tissue-specific promoter and enhancer regions ([@bib5]; [@bib14]; [@bib26]; [@bib42]). To date, factors within the liver, hippocampus, pancreas have previously been reported, however a muscle-specific transcriptional regulator has yet to be defined.

In skeletal muscle the bHLH transcription factor MYOD1 drives myogenic gene expression by recruiting co-factors and the transcriptional machinery to muscle-specific gene promoters ([@bib49]; [@bib45]; [@bib16]; [@bib7]). MYOD1 is often referred to as the 'master myogenic switch' as it is required for muscle cell differentiation and is capable of converting non-muscle cells into a muscle lineage ([@bib13]; [@bib60]). In adult skeletal muscle, BMAL1:CLOCK target the core-enhancer element (CE) located 20 kb upstream of the *Myod1* start site to promote the circadian expression of MYOD1 ([@bib1]; [@bib70]). We previously reported that MYOD1-CE mice, that only lack the upstream CE region, display significant declines in the circadian amplitude of the core clock genes *Bmal1* and *Per2 (*[@bib70]), suggesting MYOD1 may modulate core clock gene expression in skeletal muscle.

Herein, we sought to address two questions: 1) Does MYOD1 transcriptionally regulate core molecular clock genes? And 2) Does MYOD1 work with the core clock components to regulate the circadian expression of muscle specific genes? We found that MYOD1 binds to an intronic enhancer within the *Bmal1* promoter and functions to transcriptionally regulate *Bmal1* expression. Using both In vivo and In vitro approaches we determined that MYOD1 serves to enhance the amplitude of *Bmal1* expression creating a feed-forward regulatory loop between *MyoD1* and the core clock gene, *Bmal1* in skeletal muscle. We also found that MYOD1 works in a synergistic fashion with BMAL1:CLOCK to amplify the circadian expression of a muscle-specific, clock-controlled gene, *Titin-cap* (*Tcap)*. Co-localization studies demonstrated that MYOD1, BMAL1, and CLOCK are in close proximity within myonuclei. *Tcap* promoter analysis uncovered that MYOD1 and BMAL1 target a tandem E-box and that both Eboxes are required for the circadian regulation. These findings identify a novel role for MYOD1 as a clock amplifier and highlight synergistic interactions among core the clock factors, BMAL1:CLOCK and MYOD1 in regulating downstream clock-controlled gene expression in skeletal muscle.

Results {#s2}
=======

Characterization of MYOD1 binding sites in adult skeletal muscle {#s2-1}
----------------------------------------------------------------

We first noted that expression of the core clock genes *Bmal1* and *Per2* were dampened in skeletal muscle of mice in which circadian expression of *MyoD1* was abolished (MYOD1-CE mice), which suggested that MYOD1 may function as an upstream transcriptional regulator of the molecular clock ([@bib70]). To address these findings we performed a MYOD1 ChIP-Seq experiment with adult skeletal muscle from male C57BL/6J mice. We identified 12,343 MYOD1 binding sites on 7751 genes using very stringent statistics for calling peaks to minimize false positives due to our lack of a preimmune serum control ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We compared the list of genes bound by MYOD1 to a list of circadian genes identified from a high resolution time-series collection in skeletal muscle ([@bib71]). Of the 1454 circadian mRNA transcripts in skeletal muscle (JTK_CYCLE p-value \< 0.03: [Supplementary file 2](#supp2){ref-type="supplementary-material"}) we found that approximately 30% (536 genes, [Supplementary file 3](#supp3){ref-type="supplementary-material"}) are directly targeted by MYOD1 ([Figure 1A](#fig1){ref-type="fig"}) ([@bib71]). Gene ontology (GO) enrichment analysis of these 536 circadian MYOD1 target genes revealed a significant enrichment for genes involved in muscle structure and development consistent with MYOD1's known function as a myogenic transcription factor ([Figure 1B](#fig1){ref-type="fig"}, [Supplementary file 4](#supp4){ref-type="supplementary-material"}).

![MYOD1 binding coverage on skeletal muscle circadian genes.\
(**A**) Overlap of genes bound by MYOD1 (red) and circadian genes (grey) in adult skeletal muscle (JTK_CYCLE p-value \< 0.03). (**B**) Gene-ontology enrichment terms for MYOD1-bound, circadian genes in adult skeletal muscle. (**C-F**) Temporal mRNA expression profiles of MYOD1-bound, circadian genes in adult skeletal muscle from either MYOD1-CE (dotted red) or C57BL/6J (solid black, wildtype) mice. Dark shading indicates the relative dark/active phase as these mice were reared in DD at the time of collection. At each time-point RT-PCR expression values are displayed as average fold-change relative to the *Rpl26* house-keeping gene ± SEM (n = 3). Relative gene expression was calculated by the standard curve method. Results were analyzed with one-way ANOVA comparing WT vs. MYOD1-CE, \* indicates a p-value less than 0.05. (**G**) JTK_CYCLE statistics for the RT-PCR results corresponding to the temporal expression values in C-F. 'BH.Q' column reports false discover rates and 'ADJ.P' reports adjusted p-values.](elife-43017-fig1){#fig1}

To futher investigate MYOD1 as a regulator of downstream circadian gene expression we selected a subset of the MYOD1-bound circadian target genes and evaluated their temporal expression profiles in skeletal muscle from the MYOD1-CE mice. We indentified target genes for our analysis by querying a publically available MYOD1-CE expression dataset for circadian genes that are also MYOD1 targets to test if they were down-regulated in MYOD1-CE muscle tissue ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). The genes included in this analysis were the muscle-growth regulator *Asb2* ([@bib12]), the clock-output gene *Nrip1* ([@bib46]), a glycogen synthase regulator *Ppp1r3c* ([@bib34]), and the angiogenesis factor *Vegfa* ([@bib2]). Interestingly, in muscle from MYOD1-CE mice these genes displayed altered temporal expression over time of day with a significant reduction in average expression ([Figure 1C--F](#fig1){ref-type="fig"}). When we analyzed the temporal gene expression profiles with the circadian statistical program, JTK_CYCLE, we found that *Vegfa* and *Nrip1* mRNAs were no longer circadian, and for *Ppp1r3c* and *Asb2* the p-values were notably higher. These findings are consistent with a model in which MYOD1 levels influence molecular clock transcriptional output in skeletal muscle.

MYOD1 transcriptionally regulates the expression and circadian amplitude of *Bmal1* {#s2-2}
-----------------------------------------------------------------------------------

Within the subset of MYOD1 bound circadian genes we found a significant enrichment for the biological process of 'circadian rhythm' ([Figure 1B](#fig1){ref-type="fig"}) and observed MYOD1 binding within gene-regulatory regions of multiple core clock genes ([Table 1](#table1){ref-type="table"}) including a large binding peak within the *Bmal1* locus ([Figure 2A](#fig2){ref-type="fig"}). MYOD1 over-expression significantly elevated endogenous BMAL1 protein levels by approximately 50% in C2C12 myotubes ([Figure 2B](#fig2){ref-type="fig"}), suggesting that *Bmal1* is under transcriptional regulation by MYOD1. We next tested the responsiveness of a *Bmal1* promoter luciferase reporter (*Bmal1P*-Luc) to over-expression of MYOD1 via Dual-Luciferase assays in C2C12 myotubes ([Figure 2C](#fig2){ref-type="fig"}) and isolated skeletal muscle primary myotubes ([Figure 2D](#fig2){ref-type="fig"}). For these experiments we co-transfected the *Bmal1P*-Luc reporter with an empty vector control (pGEM), a MYOD1 over-expression plasmid (MYOD1), or a MYOD1 mutant expression plasmid lacking a functional transactivation domain (MYOD1 3Δ56, MYOD1mut) ([@bib43]). Over-expression of wildtype MYOD1 resulted in a significant enhancement in *Bmal1P*-Luc activity in comparison to the pGEM control or the MYOD1mut vector in both the C2C12 myotube or primary myotube cultures ([Figure 2C,D](#fig2){ref-type="fig"}). To directly test whether the *Bmal1* promoter can be transactivated by MYOD1 in adult skeletal muscle we electroporated *Bmal1P*-Luc into the tibialis anterior (TA) muscles with one leg co-transfected with pGEM control while the contralateral TA was co-transfected with a MYOD1 over-expression plasmid. We found that over-expression of MYOD1 was sufficient to significantly enhance *Bmal1P*-Luc bioluminescence in comparison to the pGEM control and the magnitude of this induction was similar to what we observed in C2C12 myotubes ([Figure 2E](#fig2){ref-type="fig"}).

![MYOD1 transactivates the *Bmal1* promoter and enhances its circadian amplitude in C2C12 myotubes.\
(**A**) UCSC genome browser visualization (mm10 genome) of MYOD1 binding tags within the *Bmal1* locus. (**B**) Representative BMAL1 western blots from C2C12 myoblasts transiently transfected with 150 ng pGEM empty vector (-) or MYOD1 expression vector (+). Densitometric values are expressed as average fold-change of BMAL1 over the Tubulin loading control which was unchanged with MYOD1 transfection ± SEM (n = 3). Results were analyzed with one-way ANOVA, \* indicates a p-value less than 0.05 (p = 0.025). *Bmal1P*-Luc luminescence in C2C12 myotubes (2**C**, n = 4 biological replicates) and skeletal muscle primary myotubes (**D**, n = 3 biological replicates) with transient transfection of pGEM control, MYOD1, or MYOD1mut expression vectors. Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ± SEM. Results were analyzed using one-way ANOVA, \*\* indicates a p-value less than 0.001. \# indicates a p-value less than 0.01 comparing MYOD1 vs MYOD1mut. (**E**) *Bmal1P*-Luc luminescence in electroporated skeletal muscle. *Bmal1P*-Luc activity was normalized to *Renilla* luciferase as an electroporation control with the right-leg receiving MYOD1 expression vector (red circles) and the left leg receiving the pGEM empty vector control (black circles). The p-value statistic was calculated by performing a Mann-Whitney non-parametric t-test. Note, one outlier was removed from each group based upon the Robust regression and outlier removal (ROUT) test, with a false discovery rate of \<0.01. *Bmal1P*-Luc Dual-Luciferase activities in skeletal muscle primary myotubes (**F-H**) Representative *Bmal1P*-Luc driven bioluminescence recordings in synchronized C2C12 myotubes co-transfected with pGEM control (F, n = 7), MYOD1 (G, n = 6), or MYOD1mut (H, n = 4) expression vectors. Luminescence recordings are expressed as average counts/sec (base-line subtracted) (**I**) Average *Bmal1P*-Luc amplitudes ± SEM calculated by JTK_CYCLE from 1.5 to 4.5 days post-synchronization. Results were analyzed with one-way ANOVA, \*\* indicates p-value less than 0.001, \# indicates p-value less than 0.002 (n = 4 biological replicates per group).](elife-43017-fig2){#fig2}
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###### MYOD1 binding sites within core clock genes from skeletal muscle ChIP-Seq.

  Gene name   Peak score   Distance to TSS   Annotation                          BH.Q       **Adj.p**   **Phase**   **AMP**
  ----------- ------------ ----------------- ----------------------------------- ---------- ----------- ----------- -----------
  *Arntl*     52.5         −215              promoter-TSS (NM_007489)            6.4E-07    1.47E-10    23          0.8400075
  *Coq10b*    17.5         −52               promoter-TSS (NM_001039710)         1.04E-05   9.47E-09    9           0.5541172
  *Per3*      15.3         84                promoter-TSS (NM_001289878)         1.46E-05   1.60E-08    10.5        0.4985951
  *Clock*     17.5         206               promoter-TSS (NM_001305222)         2.96E-05   4.38E-08    1           0.2368383
  *Tef*       23.3         397               intron (NM_153484, intron 1 of 3)   0.000268   9.96E-07    10.5        0.1759777
  *Nr1d2*     27           276               5\' UTR (NM_011584, exon 1 of 8)    0.000359   1.49E-06    9.5         0.2442347
  *Ciart*     19           −384              promoter-TSS (NM_001033302)         0.000626   3.24E-06    9           1.0158296
  *Hlf*       10.9         39                promoter-TSS (NM_172563)            0.001343   9.73E-06    11          0.3266197
  *Cry1*      16.8         −40               promoter-TSS (NM_007771)            0.026447   0.000699    19          0.0611011

We next asked if MYOD1 influences the temporal or circadian oscillatory parameters of *Bmal1* expression with real-time bioluminescence recording of synchronized C2C12 myotubes transfected with the *Bmal1P*-Luc reporter in a Lumicycle. We found that *Bmal1P*-Luc displayed a robust circadian bioluminescence activity ([Figure 2F](#fig2){ref-type="fig"}). Consistent with the data in [Figure 2A--E](#fig2){ref-type="fig"}, over-expression of MYOD1 significantly enhanced the amplitude of the *Bmal1P*-Luc oscillation by approximately 40-fold in C2C12 myotubes ([Figure 2G,I](#fig2){ref-type="fig"}) indicating a novel role for MYOD1 as a modulator of core clock amplitude in skeletal muscle. In comparison to the wildtype MYOD1 vector, co-expression with the MYOD1mut vector failed to fully transactivate *Bmal1P*-Luc ([Figure 2H](#fig2){ref-type="fig"}), and only increased the amplitude of *Bmal1P*-Luc on average \~8 fold in comparison to the pGEM control ([Figure 2H,I](#fig2){ref-type="fig"}).

MYOD1 regulates *Bmal1* via a non-canonical E-box element {#s2-3}
---------------------------------------------------------

The presence of a MYOD1 binding peak within the *Bmal1* locus ([Figure 2A](#fig2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}), together with MYOD1's ability to transcriptionally activate and enhance the amplitude of the *Bmal1P*-Luc reporter argued for the presence of a MYOD1-response element within the *Bmal1* promoter. The *Bmal1P*-Luc construct contains 394 bp upstream of transcription start (TSS) and 154 bp downstream of the TSS, and preliminary truncations experiments indicated that the region downstream of the TSS was required for MYOD1-mediated transactivation (data not shown). To identify the possible response element, we performed three targeted truncations within the downstream region of the *Bmal1P*-Luc reporter ([Figure 3A](#fig3){ref-type="fig"}): T1 (from −394 to +86), T2 (from −394 to +68) and T3 (−394 to +33). Compared with the full length *Bmal1P*-Luc reporter, the T2 and T3 truncated reporters displayed significantly decreased response to MYOD1 over-expression ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, we found a non-canonical E-box motif (5'-CAGGGA-3') within the +68 to+86 region. To determine if this site was required for the MYOD1 transactivation we performed site-directed mutagenesis (5-CAGGGA-3' to 5'-ATCTAA-3' , *Bmal1Pmut-Luc*) within the full-length reporter. The *Bmal1Pmut*-Luc reporter displayed a significantly blunted response to wildtype MYOD1 over-expression compared to the full length *Bmal1P-Luc* reporter (40 vs. 150-fold) ([Figure 3B](#fig3){ref-type="fig"}). We did note, however, that over-expression of MYOD1 was still sufficient to activate the *Bmal1Pmut*-luc reporter compared to the pGEM negative control and the magnitude of the transactivation was similar to that observed in the T2 and T3 truncation mutants. These findings argue that there is an additional cis element(s) upstream of +33 within the *Bmal1* promoter that is either directly or indirectly responsive to MYOD1 expression.

![A non-canonical E-box within the *Bmal1* promoter is required for amplification by MYOD1.\
(**A**) Representative diagram of the *Bmal1P*-Luc promoter truncation constructs. TSS indicates transcriptional start site. \* indicates the relative location of the non-canonical E-box element. FL indicates the full-length *Bmal1P*-Luc reporter. T1, T2 and T3 indicate the truncated reporters. (**B**) Dual-luciferase activities from the full-length *Bmal1P*-Luc, T1-T3, and *Bmal1Pmut*-Luc reporters (n = 4/group). Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ±SEM (n = 4). Results were analyzed using one-way ANOVA, \*\* indicates a p-value less than 0.001 in relation to the FL *Bmal1P*-Luc + MYOD1 result (p value \< 0.001), \* indicates a p-value less than 0.029 in relation to the FL *BmalP*-Luc +MYOD1 result. (**C-D**) Representative *Bmal1P*-Luc (black) and *Bmal1Pmut*-Luc (red) driven bioluminescence recordings in synchronized C2C12 myotubes co-transfected with the pGEM control vector (**C**), or MYOD1 expression vector (**D**). Luminescence recordings are expressed as average counts/sec (base-line subtracted). (**E**) Average *Bmal1Pmut*-Luc amplitudes calculated by JTK_CYCLE from 1.5 to 4.5 days post-synchronization (n = 3/group). Data are displayed as average amplitude ± SEM . Results were analyzed with one-way ANOVA, \*\* indicates p-value less than 0.001. (**F**) Representative *Bmal1P*-Luc (black) and *Bmal1Pmut*-Luc (red) driven bioluminescence recordings in synchronized skeletal muscle primary myotubes. Luminescence recordings are expressed as average counts/sec (base-line subtracted) for n = 3 biological replicates per group.](elife-43017-fig3){#fig3}

We next tested whether the MYOD1 response element identified above is required for the MYOD1-mediated enhancements to the *Bmal1P*-Luc circadian amplitude. As seen in [Figure 3C](#fig3){ref-type="fig"}, *Bmal1Pmut*-Luc displayed a \~ 24 hr circadian oscillatory pattern, but the amplitude of the oscillation was on average 50% lower than that of the wildtype *Bmal1P*-Luc reporter at basal conditions. Over-expression of MYOD1 was still able to significantly increase the circadian amplitude of the *Bmal1Pmut*-luc reporter ([Figure 3D,E](#fig3){ref-type="fig"}), however the amplitude of the *Bmal1Pmut*-Luc was only 10% of what we observed for *Bmal1P*-Luc (see [Figure 2I](#fig2){ref-type="fig"}). To extend the C2C12 results cells we also tested this region in primary myotubes and found that *Bmal1Pmut*-Luc displayed a dampened circadian amplitude compared to the wildtype *Bmal1P*-Luc reporter ([Figure 3F](#fig3){ref-type="fig"}). Taken together, these findings argue that the non-canonical E-box element located downstream of the *Bmal1* TSS is a MYOD1-response element and is required for full transactivation of the *Bmal1* promoter by MYOD1.

MYOD1 co-localizes with both BMAL1 and CLOCK within myonuclei {#s2-4}
-------------------------------------------------------------

The core molecular clock components are ubiquitously expressed in most, if not all cells, however the circadian transcriptomes in different tissues are highly divergent with approximately 5--10% overlap ([@bib71]; [@bib35]). The mechanisms that direct tissue-specific circadian gene signatures are not fully understood; however, interactions between lineage specific factors and the core clock components have previously been reported ([@bib14]; [@bib29]; [@bib42]; [@bib41]; [@bib63]). We reasoned that MYOD1 is a likely candidate for generating skeletal muscle transcriptional rhythms given that it oscillates in a robust fashion and is a master regulator of the myogenic gene program ([@bib1]). Therefore, we asked whether MYOD1 and BMAL1:CLOCK co-localize within nuclei of the C2C12 muscle cell line by performing a bimolecular fluorescence complementation (BiFC) assay.

We used a *Venus* based system with constructs tagged with either non-fluorescent *Venus* C- terminal fragments (VC) or with the non-fluorescent *Venus* N-terminal fragment (VN). With this design, *Venus* fluorescence signals are generated only when VC- and VN-tagged proteins co-localize and bring the two domains into physical association. We observed fluorescence signals within myonuclei when we co-expressed the known binding partners VN-HDAC5 with VC-MEF2c which served as a positive control and demonstrated that the BiFC assay was functional in our hands ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). In agreement with BMAL1 and CLOCK forming heterodimers, we observed nuclear fluorescent signals when we co-expressed VN-CLOCK with VC-BMAL1 ([Figure 4A](#fig4){ref-type="fig"}). We performed a series of negative control experiments by co-expressing VN-BMAL1 with the VC-control vector ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}), or VN-CLOCK with the VC-control vector ([Figure 4---figure supplement 1I](#fig4s1){ref-type="fig"}) and failed to observe fluorescent signals. As an additional negative control, we could not detect a fluorescent signal when we co-expressed VN-BMAL1 with VC-BMAL2 ([Figure 4B](#fig4){ref-type="fig"}), consistent with reports that these isoforms do not heterodimerize. Interestingly, we observed nuclear fluorescent signals when we co-expressed VC-MYOD1 with VN-CLOCK ([Figure 4C](#fig4){ref-type="fig"}) or VN-BMAL1 ([Figure 4D](#fig4){ref-type="fig"}), indicating that MYOD1 co-localizes with both BMAL and CLOCK within myonuclei. We also observed fluorescent signals when we co-express VC-CLOCK or VC-BMAL1 with VN-MYOD1 (data not shown). It was interesting to note that MYOD1 was localized with either BMAL1 or CLOCK in multiple foci within the myonucleus indicating the role of MYOD1 and the clock factors across several genomic loci. However, the pattern of MYOD1:CLOCK factor binding was more discrete when compared to the diffuse binding of BMAL:CLOCK throughout the nucleus. This suggests that MYOD1 is interacting with only a subset of the BMAL1:CLOCK heterodimers within the nucleus. However, these images provide one snapshot in time and these transcription factors have a temporal component to their function that cannot be extrapolated from these images. Future studies will focus on the temporal interactions between MYOD1 and the clock factors as well as the fundamental molecular links and likely co-factors that modulate these interactions.

![MYOD1 colocalizes with BMAL1 and CLOCK in C2C12 myonuclei.\
Representative images from the BiFC assay performed in C2C12 myoblasts co-transfected with (**A**) VN-CLOCK and VC-BMAL1, (**B**) VN-BMAL1 and VC-BMAL2, (**C**) VN-CLOCK and VC-MYOD1, and (**D**) VN-BMAL1 and VC-MYOD1. mCherry expression plasmids (red fluorescence signal) were co-transfected in each experiment to visualize the myoblasts and ensure successful transfection. Yellow fluorescence signals indicate positive co-localization via the formation of the *Venus* Luciferase.](elife-43017-fig4){#fig4}

Selection of *Titin-cap* (*Tcap*) as a model gene for studying regulatory interactions between MYOD1 and BMAL1:CLOCK in skeletal muscle {#s2-5}
---------------------------------------------------------------------------------------------------------------------------------------

Since MYOD1 co-localized with BMAL1:CLOCK, we next wanted to address if MYOD1 works with these core clock factors to regulate the circadian expression of muscle genes. To study the potential transcriptional mechanisms between MYOD1 and BMAL1:CLOCK we first performed a bioinformatics filtering paradigm to identify a model muscle-specific gene to test MYOD1 and BMAL1:CLOCK interactions ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). We started our analysis with genes that displayed robust rhythmic expression in skeletal muscle ([@bib22]; [@bib71]) by setting a JTK_CYCLE circadian p-value cutoff of \<0.001. From this list we selected genes that reach peak gene expression at the inactive to active phase transition (peak between CT 10--14) similar to known circadian genes *Dbp* or *Per2*, as we reasoned that those genes are more likely to be direct BMAL1:CLOCK targets. We further filtered our list by selected genes that are significantly down-regulated in the inducible skeletal muscle-specific *Bmal1* knockout model (iMS-*Bmal1^-/-^*) ([@bib20]). From this analysis we selected the z-line protein *Titin-cap* (*Tcap,* also known as *Telethonin)*. Given that previous reports have reported *Tcap* regulation by both MYOD1 in vitro ([@bib69]) and BMAL1 in the heart ([@bib44]), we reasoned that it is a good candidate for testing transcriptional regulatory interactions between MYOD1 and BMAL1:CLOCK.

*Tcap* is synergistically activated by MYOD1 and BMAL1:CLOCK {#s2-6}
------------------------------------------------------------

To determine if *Tcap* is regulated by BMAL1:CLOCK in skeletal muscle we performed Dual-Luciferase reporter assays in C2C12 myotubes by transfecting BMAL1 and CLOCK expression vectors with a *Tcap* promoter-Luciferase reporter (*TcapP*-Luc). We found that co-expression of BMAL1 and CLOCK (BMAL1:CLOCK) enhanced *TcapP*-Luc activity approximately 2.5-fold compared to the pGEM control ([Figure 5A](#fig5){ref-type="fig"}). Over-expression of mutant forms of either BMAL1 (BMAL1mut) or CLOCK (CLOCKmut) failed to transactivate the *TcapP*-Luc reporter suggesting that a functional BMAL1:CLOCK heterodimer is necessary to activate the *Tcap* promoter ([Figure 5A](#fig5){ref-type="fig"}). We next performed an siRNA mediated knockdown of *Bmal1* to compliment our *BMAL1mut* findings and determine if expression of endogenous *Tcap* levels are dependent on BMAL1. We found that *Bmal1* knockdown significantly reduced the expression of *Tcap* as well as *MyoD1* mRNAs in C2C12 myotubes in comparison to a non-targeting control siRNA ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These findings are in agreement with observed loss of *Tcap*'s circadian expression in iMS-*Bmal1^-/-^* mouse models ([Supplementary file 5](#supp5){ref-type="supplementary-material"}) and further demonstrate that endogenous *Tcap* expression is regulated downstream of BMAL1.

![*TcapP*-Luc is synergistically activated by MYOD1 and BMAL1:CLOCK.\
(**A**) *TcapP*-Luc Dual-Luciferase activity responses from C2C12 myotubes co-transfected with BMAL1 +CLOCK, BMAL1mut + CLOCK, and BMAL1 +CLOCKmut vectors (n = 4 biological replicates/group). Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ± SEM. Results were analyzed using one-way ANOVA, \* indicates p = 0.029. (**B**) *TcapP*-Luc Dual-Luciferase activity responses from C2C12 myotubes co-transfected with MYOD1 alone, MYOD1 +BMAL1+CLOCK, or variations of BMAL1mut, CLOCKmut, and MYOD1mut vectors. Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ± SEM (n = 4). Results from MYOD1 and MYOD1 +BMAL1:CLOCK co-transfections were analyzed using one-way ANOVA, \*\* indicates a p-value less than 0.001 in relation to the pGEM control. Results from the mutant co-transfection experiments (red) were analyzed using one-way ANOVA. \# indicates a p-value less than 0.01 relative to the MYOD1 +BMAL1:CLOCK result. (**C--E**) Representative *TcapP*-Luc driven bioluminescence recordings in synchronized C2C12 myotubes co-transfected with the pGEM control (**C**), MYOD1 (**D**), or MYOD1mut (**E**) expression vectors. Luminescence recordings are expressed as average counts/sec (base-line subtracted). (**F**) Average *TcapPmut*-Luc amplitudes calculated by JTK_CYCLE from 1.5 to 4.5 days post-synchronization. Data are displayed as average amplitude ± SEM (n = 3 biological replicates/group). Results were analyzed with one-way ANOVA, \* indicates p-value less than 0.05. (**G**) *Tcap* temporal mRNA expression profiles from muscles of MYOD1-CE (dotted red) or C57BL/6J (solid black) mice. Dark shading indicates relative dark/active phase as these mice were reared in DD at the time of collection. At each time-point RT-PCR expression values are displayed as average fold-change relative to the *Rpl26* house-keeping gene ± SEM (n = 3). Results were analyzed with one-way ANOVA comparing WT vs. MYOD1-CE at each time-point, \* indicates a p-value less than 0.05. (**H**) JTK_CYCLE statistics for the RT-PCR results corresponding to *Tcap*'s temporal expression values. 'BH.Q' column reports false discover rates and 'ADJ.P' reports adjusted p-values.](elife-43017-fig5){#fig5}

Given the observation that MYOD1 co-localized with BMAL1 and CLOCK within myonuclei, we next sought to determine whether *Tcap* is cooperatively regulated by BMAL1:CLOCK and MYOD1. Over-expression of MYOD1 resulted in a robust activation of *TcapP*-Luc (\~280 fold), while over-expression of the MYOD1mut vector failed to activate the reporter to the same degree (only 7-fold) ([Figure 5B](#fig5){ref-type="fig"}). Over-expression of MYOD1 together with BMAL1:CLOCK resulted in a synergistic activation of the *TcapP*-Luc reporter (\~540 fold) ([Figure 5B](#fig5){ref-type="fig"}), that was significantly greater than MYOD1 alone (p-value = 0.033). The cooperative interaction among these factors is further highlighted by the reduced ability of MYOD1 to transactivate *TcapP*-Luc when co-expressed with mutant forms of either BMAL1 or CLOCK. Over-expression of MYOD1 with BMAL1mut or CLOCKmut reduced the *TcapP*-Luc activity from \~540 fold to \~55 fold (BMAL1mut) and \~180 fold (CLOCKmut) ([Figure 5B](#fig5){ref-type="fig"}, p-value \< 0.01). Taken together, these results argue that BMAL1:CLOCK and MYOD1 work in a cooperative fashion to regulate *Tcap* expression.

MYOD1 enhances the circadian amplitude of *Tcap* {#s2-7}
------------------------------------------------

The *TcapP*-Luc reporter displayed a robust circadian oscillation in synchronized C2C12 myotubes ([Figure 5C](#fig5){ref-type="fig"}), and, as predicted, in an anti-phasic expression pattern compared to *Bmal1P*-Luc (as seen in [Figure 2F](#fig2){ref-type="fig"}). These findings validate that the *TcapP*-Luc reporter contains the necessary regulatory elements required for its circadian oscillation in C2C12 cells. Given that MYOD1 and BMAL1:CLOCK synergistically activated the *TcapP*-Luc reporter in our Dual Luciferase assays, we next tested whether over-expression of MYOD1 influences the circadian oscillatory parameters of *Tcap*. Over-expression of MYOD1 alone significantly elevated the circadian amplitude of *TcapP*-Luc over 20-fold ([Figure 5D,F](#fig5){ref-type="fig"}). Interestingly, over-expression of the MYOD1mut vector failed to amplify the *TcapP*-Luc rhythm to the same extent as the wildtype MYOD1 vector ([Figure 5E,F](#fig5){ref-type="fig"}). To determine if MYOD1 influences the circadian expression profile of endogenous *Tcap* mRNA, we quantified *Tcap* expression over a circadian time-course in MYOD1-CE and wildtype control muscle tissue. *Tcap* mRNA displayed a dampend expression ([Figure 5G](#fig5){ref-type="fig"}) and complete loss of circadian rhythmicity in MYOD1-CE muscle tissue in comparison to wiltype controls ([Figure 5G,H](#fig5){ref-type="fig"}). These findings are consistent with the results from the dual luciferase assays and demonstrate the requirement for both BMAL1 and MYOD1 in promoting circadian rhythm expression of *Tcap*. Additionally, the findings support the BiFC results that MYOD1 and the molecular clock factors function as a transcriptional regulatory complex in muscle.

A tandem E-box element within the *Tcap* promoter is required for its circadian expression and synergistic regulation by MYOD1 and BMAL1:CLOCK {#s2-8}
----------------------------------------------------------------------------------------------------------------------------------------------

We next sought to investigate the cis-regulatory elements within the *Tcap* promoter that are required for its circadian expression pattern and synergistic activation by MYOD1 and BMAL1:CLOCK. The *Tcap* promoter contains three canonical E-box motifs that are highly conserved in mammals ([@bib69]) which consist of a distal tandem E-box element (labelled E2-5' and E2-3') and a proximal single E-box (labelled E1) ([Figure 6A](#fig6){ref-type="fig"}). We performed site-directed mutagenesis at each of the three E-box elements within the *TcapP*-Luc reporter (*TcapP-E2-5'*-Luc, *TcapP-E2-3'*-Luc, and *TcapP-E1*-Luc) to investigate their individual role(s) in our Dual Luciferase and circadian bioluminescence reporter assays. We first evaluated the activity of these mutant reporters in response to BMAL1:CLOCK over-expression in C2C12 myotubes. BMAL1:CLOCK was still able to transactivate the E1 and E2-5' mutants, while the E2-3' mutant was unresponsive ([Figure 6B](#fig6){ref-type="fig"}). To our surprise, transactivation by MYOD1 was unaltered in all three of the *Tcap* mutants compared to the wildtype reporter ([Figure 6C](#fig6){ref-type="fig"}). However, mutation at any one of the three E-box elements completely abolished the synergistic activation by MYOD1 and BMAL1:CLOCK ([Figure 6C](#fig6){ref-type="fig"}) suggesting a complex interaction among these factors across these sites.

![Synergistic activation of the *Tcap* promoter by MYOD1 +BMAL1:CLOCK requires the tandem E-box element.\
(**A**) Graphical representation of the *TcapP*-Luc promoter:reporter construct. TSS indicates transcript start site. E1 E-box is located at −103 and E2 tandem E box is located −272 (E2 3') and −278 (E2 5') from the TSS. (**B**) Dual-Luciferase activity responses from the wildtype *TcapP*-Luc and the *Tcap* E-box mutants in C2C12 myotubes co-transfected with BMAL1:CLOCK. Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ± SEM (E2-3' and E2-5' n = 4, E1 n = 3). Results were analyzed using one-way ANOVA, \*\* indicates p-value less than 0.01 in relation to the WT *TcapP*-Luc response, \* indicates a p-value less than 0.05 in relation to the pGEM control vector. (**C**) Dual-Luciferase activity responses from the *Tcap* E-box mutants with co-transfection of MYOD1 alone or MYOD1 +BMAL1:CLOCK. Luciferase activity for each co-transfection is plotted as average fold-change in relation to the pGEM empty vector control ± SEM (n = 3). Results were analyzed using one-way ANOVA. In comparison to the pGEM control all co-transfections were significantly elevated (p-value \< 0.05), \*\* indicates a p-value of less than 0.01 in relation to the pGEM control, and \* indicates a p-value of less than 0.05 comparing *TcapP*-Luc with over-expression of MYOD1 vs MYOD1+BMAL1:CLOCK. In comparison to the pGEM control all co-transfections were significantly elevated (p-value\<0.05). . No statistical differences were observed for each of the *Tcap* mutant reporters comparing MYOD1 alone to MYOD1 +BMAL1:CLOCK. (**D-F**) Representative bioluminescence recordings from the *TcapP-E1*-Luc (**D**), *TcapP-E2-3'*-Luc (**E**), and *TcapP-E2-5'mut*-Luc (**F**) in synchronized C2C12 myotubes. (G) Representative TcapP-Luc (black, n = 3 biological replicates) and TcapPmut-E2-5'-Luc (red, n = 3 biological replicates) driven bioluminescence recordings in synchronized skeletal muscle primary myotubes. Luminescence recordings are expressed as average counts/sec (base-line subtracted).](elife-43017-fig6){#fig6}

We next performed real-time bioluminescence recordings of the *TcapP*-Luc E-box mutants to evaluate whether they are required for *Tcap*'s circadian expression pattern. We observed a normal (\~24 hr) circadian oscillatory pattern of *TcapP-E1*-Luc ([Figure 6D](#fig6){ref-type="fig"}), albeit with an \~2 fold dampening in the amplitude compared to the wildtype reporter. This is consistent with the dual luciferase results in [Figure 6C](#fig6){ref-type="fig"} that demonstate that E1 is required for full responsiveness to the synergistic regulation of MYOD1, BMAL1 and CLOCK. The real time bioluminescence assays did uncover that mutation of either the 3' or 5' tandem E-box motifs resulted in a complete loss of circadian oscillation ([Figure 6E,F](#fig6){ref-type="fig"}). In addition we found a similar pattern for *TapP*-Luc and the *TcapP-E2-5'*-Luc mutant reporter vectors in a primary myotubes ([Figure 6G](#fig6){ref-type="fig"}). These findings demonstrate that both E-boxes within the tandem E-box element are required for proper BMAL1:CLOCK-mediated regulation of *Tcap*'s circadian expression, while the E1 E-Box appears to be required for cooperative transactivation of *Tcap* by MYOD1 and BMAL1:CLOCK.

Our initial MYOD1 ChIP-Seq analysis did not yield a strong MYOD1 binding peak within the *Tcap* promoter region. Given our dual-luciferase and circadian lumicycle data we decided to test whether MYOD1 and BMAL1:CLOCK do indeed bind to the E-boxes within the *Tcap* promoter using a more targeted approach. We performed a MYOD1 and BMAL1 ChIP-PCR in adult skeletal muscle taken at ZT 2 ( two hours after lights on) with primers that incorporate either the *Tcap* tandem E-box or the E1 E-box. We found that BMAL1 was significantly enriched at both the E1 E-box ([Figure 7B](#fig7){ref-type="fig"}) as well as the tandem E-box element ([Figure 7D](#fig7){ref-type="fig"}). Interestingly, we found MYOD1 to be enriched within the tandem E-box ([Figure 7C](#fig7){ref-type="fig"}), albeit at a lower binding strength in comparison to BMAL1. We did not detect significant enrichement of MYOD1 binding to the E1 E-box element ([Figure 7A](#fig7){ref-type="fig"}). Taken together these results suggest that MYOD1 and BMAL1 regulate the circadian expression of *Tcap* via direct interactions at *Tcap*'s tandem E-box element but the weaker interaction with MYOD1 indicates that this binding may be mediated through a transcription factor complex and not direct DNA binding ([Figure 7E](#fig7){ref-type="fig"}).

![MYOD1 and BMAL1 bind to the *Tcap* tandem E-box element in adult skeletal muscle.\
(**A-B**) Chromatin Immunoprecipitation-PCR with anti-MYOD1 and -BMAL1 antibody pulldowns (and IgG controls) to detect binding of MYOD1 and BMAL1 within *Tcap*'s E1 E-box element (**A, B**) or the tandem E-box (**C, D**, primers contain 3' and 5' Eboxes). Pull-downs were performed with extracts from adult mouse quadricep muscles collected at ZT 2 (2 hours after lights on). Data are displayed as an average % of input ± SEM (n = 3 samples/group). Results were analyzed with a one-way ANOVA and \* denotes a p-value ranging from 0.02 to 0.037. (**E**) Graphical model of depicting the role of MYOD1 in modulating core clock gene expression and working as a co-factor with BMAL1:CLOCK to amplify downstream circadian genes in skeletal muscle. MYOD1 activity is modulated by extracellular signals and it amplifies *Bmal1* expression via direct transcriptional activation. BMAL1:CLOCK in turn form a positive feedback loop to regulated the circadian expression of *MyoD1* by targeting the core-enhancer element. MYOD1 and BMAL1:CLOCK work in a synergistic fashion to amplify the expression of circadian genes.](elife-43017-fig7){#fig7}

Discussion {#s3}
==========

Previous studies have demonstrated the vital importance of circadian time-keeping in skeletal muscle, however the molecular mechanisms responsible for maintaining robust clock function and circadian amplitude have yet to be identified ([@bib1]; [@bib10]; [@bib54]; [@bib18]; [@bib32]; [@bib53]). Herein we demonstrate that MYOD1 strengthens molecular clock amplitude in skeletal muscle by functioning as a direct transcriptional activator of *Bmal1*. We show that MYOD1 co-localizes with BMAL1:CLOCK in myonuclei and works in a synergistic fashion to drive the circadian expression of the muscle specific gene, *Tcap*. This study is the first to demonstrate functional roles for MYOD1 as an upstream, positive regulator of the core molecular clock, as well as a direct modulator of clock output in skeletal muscle.

Our lab previously reported that BMAL1:CLOCK rhythmically bind to the *MyoD1* promoter at the distal core-enhancer region resulting in its robust circadian expression in skeletal muscle ([@bib1]; [@bib70]). One of the main findings of our current study is that MYOD1 regulates circadian amplitude through direct transcriptional control of *Bmal1*, thus indicating that MYOD1 forms a transcriptional feed-forward loop with the molecular clock ([Figure 7E](#fig7){ref-type="fig"}). The temporal expression profile of MYOD1 correlates with its predictive role as an upstream regulator of *Bmal1*, as MYOD1 protein peaks in the mid-to-late active phase in adult skeletal muscle ([@bib1]) in anticipation of the upward rise in *Bmal1* expression which occurs during the early inactive phase. Our findings are also supported by a recent study that utilized an inducible MYOD1 expression system in human fibroblasts to define the genome architecture of human myogenic reprograming. [@bib33], found that MYOD1 activation in fibroblasts was sufficient to synchronize core circadian genes, and the authors conclude that MYOD1 may serve to communicate exogenous entrainment cues to the clock ([Figure 7E](#fig7){ref-type="fig"}). Our results provide mechanistic insights to Liu et al's findings by demonstrating that MYOD1 may sychronize the molecular clock through direct transcriptional regulation of an enhancer within the core clock gene, *Bmal1*. This transcriptional feed-forward loop between MYOD1 and the clock shares mechanistic similarities with previously identified tissue-specific, peripheral modulators of clock amplitude which A) display diurnal variations in expression and B) regulate circadian amplitude via direct transcriptional control of the *Bmal1* promoter ([@bib38]; [@bib19]; [@bib66]; [@bib46]; [@bib64]; [@bib30]; [@bib67]).

The accessory core clock transcription factors Reverbα and RORα are responsible for stabilizing period length and modulating circadian amplitude in a ubiquitous fashion across all tissues and cell-types ([@bib47]; [@bib17]; [@bib23]; [@bib57]). Both Reverbα and RORα are direct BMAL1:CLOCK target genes that compete for binding at the Rev-Erb Response element (RORE) within the *Bmal1* promoter thus forming a feedback loop where Rev-Erbα represses while RORα activates the expression of *Bmal1*. Interestingly, a number of peripheral modulators of circadian amplitude regulate *Bmal1* expression through RORα and/or REV-ERBα dependent mechanisms. For example, in liver tissue *Nrip1* promotes circadian amplitude through interacting with RORα at the *Bmal1* promoter ([@bib46]). Conversely, the glucose responsive factor *Tieg1* decreases circadian amplitude by repressing *Bmal1* expression in a REV-ERBα dependent fashion ([@bib19]; [@bib46]). Interestingly, RORα has been shown to physically interact with MYOD1 at its N-terminal activation domain to promote myogenesis ([@bib28]). Although we did not test this potential interaction in our current study, it is possible that MYOD1 regulates *Bmal1* in a RORα-dependent fashion which may help explain why the MYOD1mut vector, which lacks the transactivation domain, failed to activate the *Bmal1P*-Luc reporter ([Figure 2D,E,H](#fig2){ref-type="fig"}) to the same degree as the wildtype MYOD1 vector. Future studies will be aimed at investigating whether MYOD1 works alongside the accessory limb factors, Rev-erbα and/or RORα, to regulate *Bmal1* expression and circadian amplitude.

To investigate the potential mechanistic interactions between MYOD1 and BMAL1:CLOCK we decided to characterize their roles (both individually and together) in regulating a muscle specific circadian gene. Our bioinformatics approach led us to identify *Tcap* as a model gene for studying the interaction between MYOD1 and BMAL1:CLOCK. The novelty of these studies lie in the observations that MYOD1 and BMAL1:CLOCK work together to synergistically regulate the *Tcap* promoter. The transcriptional regulation of *Tcap* by MYOD1 appears to require a functional clock, as MYOD1-mediated activation of *TcapP*-Luc was dampened with over-expression of mutant forms of BMAL1 or CLOCK. Taken together with our findings that MYOD1 co-localizes with BMAL1:CLOCK and targets \~ 30% of the skeletal muscle circadian transcriptome, we propose a model by which MYOD1 regulates downstream circadian genes through forming cooperative interactions with BMAL1:CLOCK at cis-regulatory regions. In support of this model, a recent BMAL1 ChIP-Seq in mouse skeletal muscle revealed an enrichment for the canonical MYOD1 motif (5'-CAGCTG-3') within BMAL1 binding sites ([@bib15]).

Although the canonical BMAL1:CLOCK E-box binding sequence is CACGTG, recent studies have identified the presence of tandem E-box elements (2 E-boxes separated by six nucleotides) within a majority of core clock genes ([@bib36]; [@bib62]). Our functional characterization *Tcap*'s tandem E-box site provides a deeper understanding into the mechanisms of circadian gene regulation by MYOD1 and the clock factors. We found that the tandem E-box within the *Tcap* promoter is directly targeted by MYOD1 and BMAL1 in adult skeletal muscle and is functionally required for *Tcap*'s circadian regulation and synergistic activation by MYOD1 and BMAL1:CLOCK. In support of the BMAL1 binding enrichment within *Tcap*'s tandem E-box, we observed a loss in the circadian oscillation with either the 3' or 5' *TcapP*-Luc mutants. Furthermore, the 3', but not the 5', E-box mutant was unresponsive to BMAL1:CLOCK over-expression indicating a potential preference for BMAL1:CLOCK binding at the distal E-box. The observation that all three E-box mutants were responsive to MYOD1 over-expression, but were arrhythmic argues that *Tcap*'s circadian expression pattern is set primarily by BMAL1:CLOCK and not by MYOD1. This interpretation is in agreement with previous reports that *Tcap* oscillates and is bound by BMAL1 at the tandem E-box in heart tissue, where MYOD1 expression/activity is non-existent ([@bib44]). Taken together these findings argue that *Tcap*'s rhythmic oscillation is set primarily by BMAL1:CLOCK, while MYOD1 functions as a peripheral rheostat that controls the amplitude (i.e. gain) of the core clock mechanism and downstream clock-driven transcripts in skeletal muscle.

MYOD1's regulation of circadian amplitude may have evolved as a means for communicating muscle specific time-cues to the clock. It is well established that molecular clocks sense and respond to environmental time-cues in a tissue-specific fashion (i.e. light vs. nutrient entrainment) ([@bib44]; [@bib62]). For instance, the intrinsically photosensitive retinal ganglion cells signal light information to the SCN, while peripheral clocks, which are incapable of sensing light directly, are more responsive to feeding cues ([@bib44]). However, it is not fully understood how clocks in different tissues sense specific time-cues, but recent studies have begun to identify factors that communicate environmental signals to the clock. For instance, Oligophrenin-1 which is activated by synaptic firing, modulates the expression of *Bmal1* by sequestering REV-ERBα within the cytosol of hippocampal neurons ([@bib46]). Additionally, Hif1α which is activated during hypoxic conditions has been shown to influence clock gene expression within a number of cell types including skeletal muscle ([@bib63]). Ourselves and others have demonstrated that muscle contractions and nutrient cues serve as time cues for the clock mechnism within skeletal muscle, as forced exercise or meal timing phase shifts core clock rhythms ([@bib68]; [@bib56]; [@bib37]; [@bib32]). MYOD1 is a likely candidate for communicating these environmental time-cues to the clock, as its expression and activity is strongly influenced by nutrient signals (repressed during fasting conditions) and muscle contraction (elevated with denervated muscle tissue), both of which are strong time-cues for the skeletal muscle molecular clock ([Figure 7E](#fig7){ref-type="fig"}) ([@bib68]; [@bib56]). MYOD1 activity may also mediate information for the timing or phase of the clock rhythms as we observed phase delays in *Bmal1P*-Luc rhythms with over-expression of MYOD1 in C2C12 myotubes.

In summary, we demonstrate that MYOD1 is a critical transcription factor in the regulation of circadian amplitude and downstream rhythmic gene expression in skeletal muscle. Given the vital role clocks play in the daily maintenance of skeletal muscle physiology and metabolism ([@bib1]; [@bib10]; [@bib54]; [@bib18]; [@bib32]; [@bib53]), these findings provide potential therapeutic avenues for enhancing clock function in skeletal muscle through targeting MYOD1. The synergistic interactions observed between MYOD1 and BMAL1:CLOCK in the circadian regulation of *Tcap* may also serve as a basis for understanding how core clock components interact with tissue-specific transcriptional networks.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

All the animal procedures in this study were conducted in accordance with the guidelines of University of Florida for the care and use of laboratory animals. C57BL/6J male mice were purchased from Jackson Laboratory and the MYOD-CE mice, initially described by [@bib11],are maintained in a breeding colony within the Animal Care Services at the University of Florida.

Circadian tissue collection and RT-PCR {#s4-2}
--------------------------------------

We followed the established protocol in the circadian field for collection of tissues for circadian analysis ([@bib70]). Briefly, wildtype and MYOD1-CE mice (10--12 weeks of age) were entrained to a 12 hr light/12 hr dark (12L:12D) cycle for two weeks and then placed in total darkness for 30 hr prior to the start of the tissue collection to remove any light cues. Tissues were collected in darkness with red light from mice (n = 3/genotype) every 4 hr for 28 hr (seven time points). By circadian convention, the onset of activity for a nocturnal animal is defined as circadian time 12 (CT12) so the first collection was performed at CT18. Total RNA was extracted using Trizol Reagent (Ambion) and purified using the RNeasy mini kit (Qiagen, Cat. 74106). 1000 ng of total RNA was reverse transcribed using SuperScript III first strand cDNA synthesis system (Invitrogen, 18080--051). RT-PCR was performed on a QuantiStudio three thermal cycler (Applied Biosystems) from 20 ng of cDNA in a total volume of 20 μl containing Fast SYBR Green Master Mix (Applied Biosystems, Cat. 4385612) and 400 nM of each primer ([Supplementary file 6](#supp6){ref-type="supplementary-material"}). mRNA levels of target genes were normalized to corresponding *Rpl26* mRNA levels and relative quantification was calculated by using the standard curve method. Circadian statistics were performed with JTK_CYCLE analysis ([@bib22]) R-package to determine circadian p-values.

Targeted ChIP-PCR in adult skeletal muscle {#s4-3}
------------------------------------------

Wildtype (C57BL/6J, 10--12 weeks of age) mice were entrained to a 12 hr light:dark cycle (12L:12D) for 2 weeks. Quadricep muscles were collected from two mice (approximately 600--700 mg) at ZT2, formaldehyde cross-linked, and homogenized. Isolated chromatin was then sonicated and purified as described in ChIP-Seq methods. 20 μl of supernatant was used as input control. The remaining supernatant was split into three equal parts and incubated over-night at 4°C with antibodies for BMAL1, MYOD1, or rabbit IgG. Immune-complexes were then incubated with 20 μl protein Dynabeads A/G beads (Invitorgen 10003D, 10001D) for 2 hr. The beads were then washed with 1 ml RIPA buffer 3-times and 1 ml TE buffer once with a magnetic stand (each wash lasted approximately 5 min). DNA was eluted with 150 μl of 20 mM Tris pH 7.5, 5 mM EDTA, 0.5% SDS at 65°C for 30 min using a thermal mixer. Magnets were used to separate the beads from the supernatant, which was then transferred into fresh tubes with 6 μl of 5 M NaCl and 2 μl of proteinase K (20 ug/μl). The eluted DNA samples were incubated at 65°C over-night to reverse crosslink and DNA was recovered with a PCR purification kit (Qiagen) in 50 μl of elution buffer. ChIP-PCR was performed on a QuantiStudio three thermal cycler (Applied Biosystems) from 1.5 ul of ChIP DNA in a total volume of 20 ul containing Fast SYBR Green Master Mix (Applied Biosystems, Cat. 4385612) and 400 nM of each primer (primer sequences are located in [Supplementary file 7](#supp7){ref-type="supplementary-material"}). Relative ChIP DNA quantities were calculated with the delta-delta CT method and normalized to input DNA. This experiment was repeated two more times with total n = 3.

MYOD1 chromatin immunoprecipitation assays within adult skeletal muscle {#s4-4}
-----------------------------------------------------------------------

Given that MYOD1 protein oscillates in a circadian fashion, we collected the gastrocnemius muscle tissues from wildtype 12--14 week old male C57BL/6J every 4 hr for 24 hr and pooled six tissues (one per timepoint) prior to chromatin immunoprecipitation with an established MYOD1 antibody ([@bib9]). Approximately 800 mg of adult skeletal gastrocnemius muscle was homogenized in cell lysis buffer (10 mM HEPES, pH7.5, 10 mM MgCl~2~, 60 mM KCl, 300 mM sucrose, 0.1 mM EDTA, pH8.0, 0.1% Triton X-100, 1 mM DTT, protease inhibitors) containing 1% formaldehyde. Cross-linking was stopped after 30 min by adding glycine to a final concentration of 0.125 M. Nuclei and muscle fibers were separated by centrifugation at 25 g for 5 min. The supernatant was collected, and nuclei were spun down by centrifugation at 800 g for 5 min and re-suspended in 350 µl of RIPA buffer (20 mM Tris, pH8.0, 2 mM EDTA, pH8.0, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 140 mM NaCl). The nuclei preparation was sonicated to shear the DNA to 150--600 bp and then centrifuged at 14,000 g for 15 min. The supernatant was collected and pre-cleared with protein A/G slurry at 4°C for 1 hr. Protein A/G beads were removed by centrifugation and supernatant was split into two equal parts, which will be mixed with either MYOD1 Ab or pre-immune serum and incubated overnight at 4°C. The immune-complex was incubated with protein A/G beads slurry for 4 hr and the beads will be washed with RIPA buffer five times and TE buffer twice. DNA was then eluted twice with 250 µl of elution buffer (1% SDS and 0.1 M NaHCO~3~) for 20 min and supernatant was collected after 5 min centrifugation at high speed. 25 µl of 4 M NaCl was mixed with the 500 µl of elutant and incubated at 65°C overnight. Then 10 µl of 0.5 M EDTA, 20 µl of 1 M Tris pH 6.5 and 2 µl 10 mg/ml proteinase K was added to each sample and incubated at 55°C for 1.5 hr. DNA was recovered with a PCR purification kit (Qiagen). ChIP DNA samples from the MYOD1 pull-down were prepared for Solexa sequencing according to the Illumina protocol using methods described in [@bib9], with DNA fragments ranging in size from 150 to 600 bp.

ChIP-Seq analysis {#s4-5}
-----------------

We utilized the FastQ Groomer package to convert raw Fastq reads to Fastq-Sanger format, and then Trimmomatic was used to cut adapter and Illumina-specific sequences from the reads. We next aligned the trimmed reads to the mouse mm10 genome (provided by UCSC database) with the bowtie2 package. Samtools was utilized to convert between sam format to bam format, and then bamToBed was utilized to convert the reads into Bed format. We then utilized the HOMER software package for the remainder of our ChIP-seq processes. Briefly, we utilized the Homer package 'makeTagDirectory' to create tag directories. Due to the the lack of an pre-immune serum control for these studies we used stringent criteria for peak identification. To identify MYOD1 binding sites we utilized the 'findPeaks' package with the following parameters: style --factor --o auto with local background filtering set to 6-fold higher than the average surrounding 10kbp (-L 6). To identify peaks associated with gene promoters we utilized the 'annotatePeaks.pl' package with the mm10 mouse genome. The package 'makeUCSCfile' was used to create a bedgraph formatted file to visualize MYOD1 binding peaks with the UCSC genome browser (mm10 genome). To identify MYOD1 binding sites that are assocated with known circadian genes in skeletal muscle, we queried the skeletal muscle circadian transcriptome data downloaded from Circadb (<http://circadb.hogeneschlab.org/>). We utilized a JTK_CYCLE circadian p-value cutoff of 0.03 for identifying circadian transcripts in skeletal muscle. GEO accession number for raw ChIP-Seq data: GSE122082.

Gene-Ontology enrichment analysis {#s4-6}
---------------------------------

The findGO.pl package within HOMER was used to perform functional enrichment analyses of provided gene lists in the form of Entrez gene IDs, with organism set to 'mouse'.

Plasmids {#s4-7}
--------

Clock gene promoters were cloned into pGL3 basic vector based on MYOD1 binding sites identified by MYOD1 ChIP Seq. *Bmal1* promoter (−400 to +154) was amplified from mouse genomic DNA and cloned into pGL3 basic vector and was a gift from Dr. John Hogenesch, Cincinnati Children\'s Hospital Medical Center ([@bib50]). The wild-type expression vectors used in this study include: *MyoD1*, *Bmal1*, *Clock*. The *Bmal1*mut vector (Bmal1-R91A) was a gift from Dr. Takahashi from the University of Texas Southwestern ([@bib21]). The *Clock*mut vector was generated by cloning the mutant Clock^Delta19^ sequence ([@bib25]) into pcDNA3.1. The MYOD1mut (MYOD1Δ3--56) construct was a gift from Dr. Rudnicki at the Ottawa Hospital Research Institute ([@bib43]). The control plasmid we used as an empty vector control was the pGEM vector from Promega. As the pRLnull responds highly to MYOD1 expression in C2C12 myotubes, we mutated the responsive E-box and we used the mutant form of pRLnull to normalize transfection. The *Bmal1P*-Luc reporter contains the wiltype *Bmal1* promoter sequence starting 394 bp upstream of transcription start (TSS) and ending 154 bp downstream of the TSS and was a gift from Dr. Takahashi ([@bib3]). The *Tcap* luciferase promoter-reporter construct (*TcapP*-Luc) was a gift from Dr. Davie from Southern Illinois University School of Medicine and contains a 421 base pair promoter fragment that spans from −421 to +1 of the translational start site ([@bib69]). BOS-EF1a-cVenus210-matr3 and BOS-EF1a-nVenus-matr3 were gifts from Dr. Edgardo Rodriguez-Lebron at University of Florida. For Bimolecular fluorescence complementation study, *Bmal1*, *Bmal2, Clock* and *MyoD1* genes were cloned into BOS-EF1a-cVenus210, downstream of C terminus fragment of venus protein(VC), or cloned into BOS-EF1a-nVenus 210, downstream of N terminus fragment of venus protein (VN). pcDNA3.1 HA VC, pcDNA3.1 HA VN, pcDNA3.1 HA-HDAC5-VN and pcDNA3.1 HA-MEF2C-VC are gift from from Dr. Olivier Kassel from Karlsruhe Institue of Technology of Germany. For Bimolecular fluorescence complementation study, *Bmal1, Bmal2, Clock and MYOD1* genes were either cloned into pcDNA3.1 HA linker VN (venus N) vector, upstream of N terminus fragment of *Venus* protein, or cloned into pcDNA3.1 HA linker VC (venus C) vector, upstream of C terminus fragment of *Venus* protein. All cloned constructs were confirmed by DNA sequencing.

Western blot {#s4-8}
------------

C2C12 myoblasts were obtained from ATCC. Myoblasts were transiently transfected with 150 ng of either pGEM or MYOD1 expression vectors and cells were placed into fresh GM for 24 hr ([@bib1]). Following the 24 hr incubation, myoblasts were washed with ice-cold PBS and then lysed with RIPA buffer. 50 ug of protein from whole-cell lysates were loaded into each well for SDS-PAGE (10%). Proteins were transferred with a semidry apparatus onto PVDF membrane and then blotted with anti-BMAL1 Ab (Sigma SAB4300614, rabbit source, 1:1000) or anti-tubulin (Sigma T6557, mouse source, 1:1000) antibodies. Secondary Ab F(ab')2-goat anti-rabbit IgG (H + L) HRP or F(ab')2-goat anti-mouse IgG (H + L) HRP (1:10000) were applied and the blot was visualized by using Bio-Rad imager. Each lane represents a separate independent experiment (n = 3 biological replicates). BMAL1 bands were quantified with ImageJ software and normalized to the tubulin loading control.

Site-directed mutagenesis {#s4-9}
-------------------------

The QuikChange II Site-Directed Mutagenesis Kit was used to mutate the E-box element in the proximal promoter region of the *TcapP*-Luc, *Bmal1P*-Luc vector and pRLnull according to the manufacturer's instructions. The forward and reverse primer sequences are located in [Supplementary file 8](#supp8){ref-type="supplementary-material"}. The E-box CAGGTG is located in *pRL null* T7 promoter, at −59 to −64 of T7 promoter transcription start site. Genetic mutations were confirmed by DNA sequencing.

Isolation of skeletal muscle primary cells {#s4-10}
------------------------------------------

Skeletal muscle primary cells were isolated as previously described ([@bib31]). Briefly, hind-limb muscles from 8 week old from 2 C57/Bl6J mice were collected and minced in wash media containing Ham's F-10 supplemented with 10% fetal bovine serum (FBS) and 1% Streptomycin/Penicillin. Muscle tissues were then incubated in 800 U/ml Collagenase type II solution (Worthington, Cat. LS004176) at 37°C for 1 hr with gently agitation. After centrifugation, pellets were resuspended in wash media supplemented with 1000 U Collagenase type II and 11 U Dispase (Gibco, Cat. 17105--041), and incubated at 37°C for 30 min with gently agitation. Next, samples were triturated with a 20-gauge needle, centrifuged and resuspended in wash media. Cell suspensions were filtered using a 40 μm nylon cell strainer (Fisher Scientific, Cat. 22363547), centrifuged, and resuspended in Ham's F-10 supplemented with 20% FBS, 1% Streptomycin/Penicillin, and 2.5 ng/ml basic fibroblast growth factor (bFGF, PeproTech, Cat. 100-18B-100UG). Cells were pre-plated for 30--40 min in an uncoated dish. Unattached cells were transferred to ECM-coated (ECM Gel from Engelbreth-Holm-Swarm murine sarcoma, Sigma, E1270) dishes. Plates were incubated at 37°C, 5% CO~2~. Media was replaced until day three after plating, thereafter, media was replaced every 2--3 days.

Dual-Luciferase assay {#s4-11}
---------------------

Luciferase assays were performed from lysates of C2C12 myotubes cell lines ([@bib1]) or skeletal muscle primary myotubes. In each reaction 50 ng of Luciferase reporter plasmid and 150 ng of expression vectors were transfected with X-tremeGENE 9 (Roche) into C2C12 myoblasts or skeletal muscle primary myoblasts in 24-well plates (50,000 cells per well). 5 ng pRL null plasmid was used as a transfection control for C2C12s, while 6 ng pRL null plasmid were used with the skeletal muscle primaries. C2C12 myoblasts were transfected immediately after trypsin digestion, while skeletal muscle primary myoblasts were transfected 24 hr post seeding. After incubation for 24 hr, cells were switched into growth medium (GM) for an additional 24 hr before being switch into differentiation medium (DM) for another 24 hr. Luciferase activity was measured by the Promega Dual Luciferase assay system. *Firefly* luciferase activity was normalized to *Renilla* luciferase activity. The sample size for each experiment reflects n = 3--5 biological replicates per group based on previous data ([@bib70]). Luciferase activity for each transfection are plotted as average fold-change in relation to the pGEM empty vector control ±SEM. Results were analyzed using one-way ANOVA with p set at 0.05.

Real-time bioluminesence recordings {#s4-12}
-----------------------------------

Co-transfections were performed as described in the previous sections. Approximately 300 ng of luciferase reporter vectors were transfected per 35 mm dish. Expression plasmids or negative controls (pGEM) were co-transfected with approximately 500 ng per 35 mm dish. C2C12 myoblasts and skeletal muscle primary myoblasts were plated with the at 300,000 cells per 35 mm dish. C2C12 myoblasts were transfected at the time of plating with transfection/DNA mix, incubated in GM for 48 hr, and then switched to DM to induce differentiation for 4-full days (DM refreshed every other day). Skeletal muscle myoblasts were incubated with the transfection mix for 24 hr then incubated in fresh GM for an additional 24 hr prior to being switched into DM media for 3-full days. After differentiation, the myotubes (C2C12s and primaries) were synchronized with dexamethasone (1μM) for 90 min, and then washed with 1xPBS twice and 1.5 mL of Recording buffer was added (DMEM-Phenol Red free, 10 mM HEPES, luciferin 0.1 mM, 1% Pen/Strep, 2% Horse Serum, sodium bicarbonate 350 mg/L ([@bib70]). Cells were then air-tight sealed and placed in the Lumicycle apparatus. A 32-well turn table is fully automated so that the photomultiplier tubes captured and recorded the number of photons given off by each culture dish at ten minute intervals. The luminometry data was stored as photon counts/second on a computer using the Lumicycle software by Actimetrix. Circadian statistics were performed with JTK_CYCLE analysis ([@bib22]) R-package to determine circadian amplitude. The sample size for each experiment reflects n = 3--5 biological replicates per group based on previous data ([@bib70]). Average amplitude data were obtained and results were analyzed using one-way ANOVA.

Bimolecular fluorescence complementation assay (BiFC) {#s4-13}
-----------------------------------------------------

We followed procedures modified from [@bib24]. To visualize the interaction between transcription factors used a protein harboring *Venus* protein N-terminal fragments and proteins harboring *Venus* protein C-terminal fragments, 250 ng of each of these two plasmids were transiently co-transfected with 100 ng mCherry using X-tremeGENE 9 DNA transfection reagent (Roche) into C2C12 myoblasts. C2C12 density was 2 × 10^4^ cell per well of eight-well chamber slide (Ibidi, Martinsried, Germany). Fluorescence was visualized using a Leica SP8 confocal microscope 24 hr post transfection.

In vivo plasmid electroporation and biolumensence recording {#s4-14}
-----------------------------------------------------------

Electroporation of tibialis anterior (TA) muscles was conducted as described previously with modification ([@bib55]). Mice were acutely anesthetized with isoflurane gas (5%, induction; 3% maintenance) delivered via a nose cone. Each TA muscle was injected, through the skin, with 20 μl of 1xPBS containing the combined plasmid constructs. The plasmids were 10 μg of either MYOD1 expression plasmid (right TA) or pGEM control plasmid (left TA), 2 μg of *Renilla* luciferase plasmid, and 20 μg of the *Bmal1P*-Luc reporter. Following injection, electric pulses were delivered using an electric pulse generator (Electro Squareporator ECM 830; BTX, Hawthorne, NY, USA) by placing conducting gel and paddle-like electrodes on the skin on either side of the muscle. Five pulses were delivered in 200 ms interpulse intervals, each with an effective intensity of 50 V/cm and 20 ms duration, as previously used ([@bib48]). These electroporation parameters have been shown not induce muscle damage ([@bib51]; [@bib52]). Four days following electroporation, TA muscles were collected, homogenized in passive lysis buffer, and luminescence was recorded. Differences in the ratio of *Firefly* luciferase (*Bmal1P*-Luc) luminescence to *Renilla* luciferase luminescence for MYO1/*Bmal1P*-Luc/pRL null (right TA) vs pGEM/*Bmal1P*-Luc/pRL null (left TA) were assessed using a Mann-Whitney non-parametric t-test (Prism8, GraphPad). One outlier was removed from each group based upon the Robust regression and outlier removal (ROUT) test, with a false discovery rate of \<0.01.

Bmal1 siRNA knockdowns {#s4-15}
----------------------

C2C12 myoblasts were plated at a density of 60,000 cells/well in 12-well plates. Cells were transfected with 30 nM *Bmal1* siRNA (Santa Cruz Biotech, Cat. sc-38166) or 30 nM control non-targeted siRNA-A (Santa Cruz Biotech, Cat. sc-37007) using Lipofectamine 3000 as transfection reagent. After incubation for 24 hr, media was replaced with fresh GM for an additional 24 hr before being switched into DM for another 24 hr. Total RNA was extracted using Trizol Reagent (Ambion) and purified using the RNeasy mini kit (Qiagen, Cat. 74106). 1000 ng of total RNA was reverse transcripted using SuperScript VILO cDNA synthesis master mix (Invitrogen, 11754--050). RT-PCR was performed on a QuantiStudio three thermal cycler (Applied Biosystems) from 20 ng of cDNA in a total volume of 20 μl containing Fast SYBR Green Master Mix (Applied Biosystems, Cat. 4385612) and 400 nM of each primer ([Supplementary file 9](#supp9){ref-type="supplementary-material"}). *Rpl26* was used as reference gene for normalization, and relative mRNA expression values were calculated with the delta-delta CT method (2^--∆∆Ct^).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"MYOD1 functions as a clock amplifier as well as a critical co-factor for downstream circadian gene expression in muscle\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kevin Struhl as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: James Ryall (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript from Hodge et al. addresses the exciting field of circadian rhythms. Specifically asking how the clock is regulated in a tissue specific manner. To date, numerous manuscripts have shown an important role for circadian rhythms, however few have addressed the regulators of the rhythm itself. In this manuscript the authors demonstrate that *MyoD1* regulates the amplitude of the clock and that *MyoD1* regulates a muscle specific gene, *Tcap* in a clock dependent manner. This work is exciting and timely. In addition, the experiments are performed to a high standard with appropriate conclusions. There two major concerns that the authors need to address; 1) the overreliance of C2C12 cells, 2) the binding/recruitment between BMAL1, MYOD1 and *TCap*.

Essential revisions:

1\) The major limitations of this study are related to the sole use of C2C12 cell line and overexpression of MYOD1 and clock regulators. In addition the effects of MYOD1 and BMAL1:CLOCK are evaluated on transfected luciferase reporters. Performing any of the in vitro experiments in primary myogenic cells would suffice.

2\) Primary myoblasts derived from MYOD1 knock-out experiments could be employed to validate some of the findings reported here. Do the 536 clock genes identified as MYOD1 lose circadian regulation in MYOD1^-/-^ primary myoblasts? Does reconstitution with MYOD1 restore their circadian expression? Expression of a small subset of the 536 genes could be evaluated by RT-qPCR.

3\) My major query for the authors is why the *MyoD1* ChIPseq did not identify *Tcap* as a direct target and yet in vitro luciferase experiments demonstrated a clear response to *MyoD1* alone? This is worrisome as it could suggest that the in vitro studies utilizing an immortalized cell line do not represent the in vivo condition, especially as *Tcap* has only previously been found to be regulated by *MyoD1* in vitro (Zhang et al., 2011). Another possible explanation for this discrepancy could be due to the use of proliferating cells (versus terminally differentiated muscle for the ChIPseq). It would be useful for the investigators to determine whether their model holds true in differentiated C2C12 cells and/or primary cells. Alternatively, evidence of circadian *Bmal1* binding to the Ebox regions of *Tcap* in skeletal muscle (via ChIP-PCR) would provide strong support for the hypothesis.

4\) Is BMAL1 co-recruited at a subset of the 536 MYOD1-target circadian genes by *Bmal1* ChIP assay? Does MYOD1 interact with the non-canonical E-box at the *Bmal1* and tandem E-box *Tcap* regions? These data should already be available to the authors.

5\) Electroporation of *Bmal1-Luc* and *Tcap-Luc* (WT and mutant constructs) in skeletal muscle of control and MYOD1 knock-out mice would allow to convincingly address the role of MYOD1 in regulating circadian regulation of BMAL1 and *Tcap* via the identified E-boxes in a physiological setting.

10.7554/eLife.43017.026

Author response

> Essential revisions:
>
> 1\) The major limitations of this study are related to the sole use of C2C12 cell line and overexpression of MYOD1 and clock regulators. In addition the effects of MYOD1 and BMAL1:CLOCK are evaluated on transfected luciferase reporters. Performing any of the in vitro experiments in primary myogenic cells would suffice.

To address the concerns with our reliance on C2C12 myotubes, we added new in vitro experiments in which we use primary muscle cells isolated from mouse hindlimb muscles. This new data has been added to Figures 2, 3 and 6 and compliments our initial findings in C2C12 myotubes. We performed a dual-luciferase reporter assay in a similar fashion to the experiments performed in C2C12 myotubes (Figure 2C) and found that cotransfection with the wildtype MYOD1 expression vector, but not the MYOD1 mutant vector, was sufficient to significantly transactivate the *Bmal1*-Luc reporter in primary myotubes (Figure 2D). Also in Figure 2 we include new data in which we used in vivo electroporation to demonstrate that the *Bmal1* promoter is strongly transactivated by MYOD1 in tibialis anterior muscles of mice. We also performed real-time bioluminescence recordings in synchronized myotubes generated from primary muscles cells. In Figure 3F we demonstrate that the wildtype *Bmal1P*-Luc reporter oscillated in a circadian fashion, while the *Bmal1Pmut*-Luc reporter failed to oscillate with the same amplitude. In Figure 6G we show that synchronized primary myotubes co-transfected with wildtype *TcapP*-Luc display a greater bioluminescence amplitude than those transfected with the mutant *TcapP-E2-5'*-Luc reporter. Taken together these data with the use of primary cells and in vivo electroporation all consistently reinforce our findings originally obtained in C2C12 myotubes.

The second concern in this point was about reliance on overexpression strategies and we agree that our initial submission relied heavily on the use of over-expression plasmids for gain/loss of function analysis and promoter-reporter luciferase reporters to assay gene regulation. In our revised submission we have provided additional in vivo data to complement our promoter:reporter findings. Firstly, we have evaluated circadian gene expression via RT-PCR analysis in adult muscle tissue from MYOD1-CE mice and wildtype controls. MYOD1CE mice were chosen for our study given that they have constitutively low levels of *MyoD1* expression and could therefore serve as an in vivomodel of *MyoD1* knockdown. The MYOD1-CE mice been used by my lab in our paper Zhang et al., 2012, and the original reference for the mice is: Chen and Goldhamer, 2004.

From these analyses we found that circadian genes that are targeted by MYOD1 in our ChIP-seq analysis (*Ppp1R3c, Asb2, Nrip1*, and *Vegfa*) displayed significant reductions in expression with marked alterations to their circadian gene expression profile (Figure 1). Additionally, we found that circadian expression of *Tcap* mRNAis lost in MYOD1-CE muscle and this adds to the data in Figure 5. We also performed siRNA mediated knockdown of *Bmal1* in C2C12 myotubes and found a significant decrease in expression of endogenous *Tcap* and *MyoD1* mRNA levels (these data are now Figure 5---figure supplement 1).

> 2\) Primary myoblasts derived from MYOD1 knock-out experiments could be employed to validate some of the findings reported here. Do the 536 clock genes identified as MYOD1 lose circadian regulation in MYOD1^-/-^ primary myoblasts? Does reconstitution with MYOD1 restore their circadian expression? Expression of a small subset of the 536 genes could be evaluated by RT-qPCR.

Our MYOD1 ChIP-seq allowed us to identify 536 circadian genes that are direct targets of MYOD1 in skeletal muscle. We agree with the reviewers that MYOD1 loss of function experiments would help to validate our claim that MYOD1 regulates the circadian expression of these genes. To address this issue we decided to utilize the MYOD1-CE mice for two reasons. Scientifically these mice have been previously characterized as having low *Myod1* expression in adult skeletal muscle compared to wildtype control mice. Pragmatically, we have the MYOD1-CE mice in our breeding facility at UF but we do not maintain the MyoD^-/-^ mice. To obtain the mice, get through quarantine and breed them up would have pushed these experiments well beyond the 2 month deadline provided by *eLife*.

For this manuscript we collected gastrocnemius muscles over a circadian timecourse from wildtype and MYOD1-CE mice. We chose a subset of potential candidate genes from the list of the 536 circadian genes targeted by MYOD1 in our ChIPseq experiment. The genes we chose to analyze included robust circadian genes and are the following: *Ppp1r3c, Vegfa, Asb2*, and *Nrip1*. We performed RT-qPCR on the RNA to determine if their circadian pattern and/or magnitude of expression were altered in the muscle of the MYOD1 knockdown mouse (MYOD1-CD). We found that all 4 genes displayed significant alterations in circadian mRNA expression patterns as indicated by JTK_CYCLE analysis (data now in Figures 1C-G).

> 3\) My major query for the authors is why the MyoD1 ChIPseq did not identify Tcap as a direct target and yet in vitro luciferase experiments demonstrated a clear response to MyoD1 alone? This is worrisome as it could suggest that the in vitro studies utilizing an immortalized cell line do not represent the in vivo condition, especially as Tcap has only previously been found to be regulated by MyoD1 in vitro (Zhang et al., 2011). Another possible explanation for this discrepancy could be due to the use of proliferating cells (versus terminally differentiated muscle for the ChIPseq). It would be useful for the investigators to determine whether their model holds true in differentiated C2C12 cells and/or primary cells. Alternatively, evidence of circadian Bmal1 binding to the Ebox regions of Tcap in skeletal muscle (via ChIP-PCR) would provide strong support for the hypothesis.

We appreciate this reviewer's concern about use of proliferating vs. differentiated cells but one thing we need to clarify is that all the transfection data in this manuscript come from experiments performed on differentiated myotubes or muscle tissue and not myoblasts. We have gone through the manuscript to make sure that point is very clear as we agree that what is detected in myoblasts does not always correspond to the differentiated myotube/muscle tissue. In addition, as noted above we now include a number of new experiments in which we used primary muscle cells differentiated into myotubes as well as in vivo muscle tissue to strengthen the study.

The other concern noted is that we did not detect MYOD1 binding on the Tcap promoter in our ChIPseq data set. This was perplexing to us but between our transfection outcomes coupled with our BiFC data and the results from a different lab that showed MYOD1 binding within the *Tcap* promoter via ChIP-PCR during embryonic muscle development we felt that maybe MYOD1 might be more functioning as part of a complex that could get disrupted in the ChIP preparation. For the revisions, we went back to muscle tissue and worked on the crosslinking conditions and performed targeted ChIP-PCR to directly test if MYOD1 does indeed target the *Tcap* promoter. We included primers for both the Tandem E-box element as well as the E1 E-box element. With this approach we found a significant enrichment for MYOD1 binding within the tandem E-box (Figure 6C) but no significant enrichment of MYOD1 for the E1 E-box (Figure 6A). Additionally, we also have included data showing strong BMAL1 binding enrichment for the tandem E-box (Figure 6D) and the E1 E-box (Figure 6B).

> 4\) Is BMAL1 co-recruited at a subset of the 536 MYOD1-target circadian genes by Bmal1 ChIP assay? Does MYOD1 interact with the non-canonical E-box at the Bmal1 and tandem E-box Tcap regions? These data should already be available to the authors.

We agree that demonstrating that BMAL1 also targets the subset of 536 MYOD1-target circadian genes would greatly strengthen the interpretation that BMAL1 is co-recruited to these genes by MYOD1 but it is beyond the scope of our time to do *Bmal1* ChIPseq within a 2 month window. However, we did query a recently published BMAL1 ChIP-seq dataset also performed in adult skeletal muscle (Dyar et al., 2018). Of the two BMAL1 ChIP-seq biological replicates we found that there was overlap of approximately 48% to 78% of the 536 MYOD1-target circadian genes. While the range was quite variable between the two Bmal1 ChIPseq replicates there seems to be around 50% or more coverage with both MYOD1 and BMAL1 supporting our concept that this mechanism goes beyond regulation of Tcap.

> 5\) Electroporation of Bmal1-Luc and Tcap-Luc (WT and mutant constructs) in skeletal muscle of control and MYOD1 knock-out mice would allow to convincingly address the role of MYOD1 in regulating circadian regulation of BMAL1 and Tcap via the identified E-boxes in a physiological setting.

We agree with this reviewer and we provide new in vivodata showing that the *Bmal1P*-Luc reporter is transactivated by MYOD1 in adult skeletal muscle. For these experiments we electroporated the tibialis anterior muscle with *Bmal1P*-Luc with MYOD1 or +pGEM(control). The magnitude of *Bmal1* activation is similar to what we found with our in vitro studies (new data are included in Figure 2E).

To address *Tcap* regulation in vivo, we quantified *Tcap* mRNA levels over a circadian time-course in MYOD1CE skeletal muscle, and found a complete loss of circadian expression (Figure 6G, H). These data indicate that MYOD1 expression influences the expression and amplitude of both the core molecular clock as well as downstream circadian genes in skeletal muscle.
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